secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001654954-23-001174
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040
--------------------------------------------------------------------------------

- USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.
- No FDA-approved treatments exist for PH-HFpEF, which affects over 1.5 million patients in the US.
- HELP Study showed levosimendan improved 6-minute walk distance by 29 meters (p=0.03); FDA accepted endpoint for Phase 3.
- Patent builds on existing U.S. Patent No. 11,213,524 for subcutaneous levosimendan issued Jan 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423001174/0001654954-23-001174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423001174/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-001174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer